Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Stock Short Interest Report for October

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 1 shares, a drop of 99.8% from the October 15th total of 580 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 2,297 shares, the days-to-cover ratio is currently 0.0 days.

Molecular Partners Trading Up 0.3%

NASDAQ:MOLN traded up $0.01 on Tuesday, reaching $3.10. 976 shares of the stock traded hands, compared to its average volume of 2,059. Molecular Partners has a 1-year low of $3.09 and a 1-year high of $5.36. The company’s 50 day moving average is $3.86 and its 200-day moving average is $4.15. The firm has a market capitalization of $125.18 million, a price-to-earnings ratio of -1.85 and a beta of 1.17.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings results on Thursday, October 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. On average, equities research analysts forecast that Molecular Partners will post -1.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, October 2nd. HC Wainwright reissued a “buy” rating on shares of Molecular Partners in a research note on Monday, November 2nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways. Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.